Dr. Lucie Germain, Ph.D., is a full professor at the Department of Surgery and Vice Dean of Research and Graduate Studies at Laval University. Within the CHU de Québec-Laval University Research Center, she was Director of the Regenerative Medicine Division until 2014. Her work, dedicated to postnatal stem cells and human tissue reconstruction, led to three clinical trials involving engineered tissues produced in vitro applied to the treatment of venous ulcers, severely burned patients and limbal stem cell deficiency of the cornea. Dr. Germain has published more than 155 peer-reviewed articles, 67 book chapters and reviews and given more than 135 invited seminars and conferences. Her sustainable contribution as health research was recognized by the Foundation scheme of Canadian Institutes of Health Research, which allowed her a financial support for seven years in 2015. The Canada research chair program also recognized Dr. Germain as a leader in the field of stem cells and regenerative medicine by granting her a junior Tier-2 chair in 2001 and a senior Tier 1 chair in 2015. In 2013, she was nominated Member of the Canadian Academy of Health Sciences and was appointed Vice-Dean of Research and Graduate Studies at the Faculty of Medicine of Laval University in 2014.

Improving patients care through the application of her research is at the heart of her motivations. She holds the Research Chair on tissue-engineered organs and translational medicine from the Foundation of Laval University. Her research is dedicated to the reconstruction of human tissues, mainly skin, cornea, blood vessels and heart valves for experimental and clinical applications. The tissue-engineered models developed by Dr. Germain are designed for physiological, pathophysiological or pharmacotoxicological studies. Her research aims to better define molecular signaling pathways involved in stem cell regulation and differentiation. Her work also focuses on improving functionality of reconstructed tissues, for example by adding melanocytes to skin substitutes to improve their pigmentation and UV protection. An important part of her research aims to shorten the time required to produce skin substitutes and to develop a serum-free culture medium for cell and tissue culture. Finally, Dr. Germain actively works on strategies aimed at integrating tissue engineering and gene therapy to find new treatments for genetic skin disorders such as epidermolysis bullosa.

1401, 18e Rue
Québec, Québec
Canada G1J 1Z4
234 entries « 24 of 24 »

Germain L, Noël M, Gourdeau H, Marceau N

Promotion of growth and differentiation of rat ductular oval cells in primary culture

Journal Article

Cancer Res, 48 (2), 1988.

Abstract | Links:

Marceau N, Germain L, Goyette R, Noel M, Gourdeau H

Cell of origin of distinct cultured rat liver epithelial cells, as typed by cytokeratin and surface component selective expression

Journal Article

Biochem Cell Biol, 64 (8), 1986.

Abstract | Links:

Marceau N, Germain L, Baribault H

[The cytoskeleton, cellular differentiation and tumor typing]

Journal Article

Union Med Can, 114 (9), 1985.

| Links:

Germain L, Goyette R, Marceau N

Differential cytokeratin and alpha-fetoprotein expression in morphologically distinct epithelial cells emerging at the early stage of rat hepatocarcinogenesis

Journal Article

Cancer Res, 45 (2), 1985.

Abstract | Links:

234 entries « 24 of 24 »
Signaler des ajouts ou des modifications

Active projects

  • A multicenter skin research group focusing on novel treatment for epidermolysis, from 2022-12-01 to 2023-11-30
  • Allogeneic dermis to accelerate the production of a tissue-engineered skin substitute to treat Canadian burn patients, from 2023-04-01 to 2025-01-31
  • Cellules souches stromales de cornées humaines pour développer de nouvelles thérapies tissulaires dans le traitement des plaies cornéens, from 2023-03-01 to 2024-03-31
  • Chaire de recherche du Canada en Cellules Souches et Génie Tissulaire, from 2022-01-01 to 2028-12-31
  • Chaire de recherche sur les organes reconstruits en laboratoire et leurs applications cliniques, from 2013-05-01 to 2023-12-01
  • Clinical trial of cultured epithelial corneal autografts for the treatment of Canadians with limbal stem cell deficiency, from 2023-04-01 to 2025-01-31
  • Combining tissue-engineered skin with ex vivo gene therapy correction to develop a treatment for epidermolysis bullosa, from 2022-04-01 to 2024-03-31
  • Projets structurants ThéCell 2023-2024_Greffons d’épiderme autologue en combinant thérapie génique et génie tissulaire pour traiter l’épidermolyse bulleuse jonctionnelle, from 2023-04-01 to 2024-03-31
  • Recherche en vue de développer un traitement pour les patients atteints d'épidermolyse bulleuse dystrophique, from 2021-09-14 to 2025-12-31
  • Régénération de la peau humaine : Une peau reconstruite par génie tissulaire pigmentée produite plus rapidement pour traiter les patients grands brûlés, from 2022-07-01 to 2027-06-30
  • Soutien à la recherche dans le domaine des maladies auto-immunes et de la cicatrisation, from 2016-04-01 to 2027-03-31
  • Tissue engineering to treat Canadian burn patients: the Self-Assembled Skin Substitutes (SASS), from 2022-04-01 to 2025-03-31
  • Tissue-engineered solutions for uro-genital reconstruction, and replacing banned synthetic meshes, from 2021-10-01 to 2026-09-30

Recently finished projects

  • Chaire de recherche du Canada EN CELLULES SOUCHES ET GÉNIE TISSULAIRE, from 2015-01-01 to 2021-12-31
  • Cultured epithelial corneal autografts for the treatment of canadians with limbal stem cell deficiency, from 2020-01-01 to 2023-01-31
  • La réponse immunitaire aux peaux reconstruites avec des cellules allogéniques., from 2022-04-01 to 2023-03-31
  • Les cellules souches épithéliales et le génie tissulaire : de la recherche fondamentale à la recherche clinique., from 2015-07-01 to 2022-06-30
  • Monitoring expression of the transcription factors Sp1 and NFI as markers of cell quality in human corneal epithelial cells cultured on different cell carriers, from 2021-02-01 to 2022-03-31
  • Self-Assembly Skin Substitutes (SASS) for the treatment of acute wounds of Canadian burn patients, from 2020-01-01 to 2023-01-31
  • Skin Investigation Network of Canada (SkIN Canada), from 2020-01-01 to 2022-12-31
  • The Canadian National Transplant Research Program : Increasing Donation and Improving Transplantation Outcomes, from 2013-04-01 to 2022-03-31
  • Tissue-engineered solutions for uro-genital reconstruction, and replacing banned synthetic meshes, from 2021-03-01 to 2022-02-28
  • Towards an epidermolysis bullosa clinical trial with tissue-engineered skin after ex vivo gene therapy correction, from 2020-08-01 to 2023-01-31
Data provided by the Université Laval research projects registery